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Background: Biological agents provide an important therapeutic alternative for rheumatoid 
arthritis patients refractory to conventional disease-modifying antirheumatic drugs. Few head-
to-head comparative trials are available.
Purpose: The aim of this meta-analysis was to compare the relative efficacy of different biologic 
agents indicated for use as monotherapy in rheumatoid arthritis.
Methods: A systemic literature search was performed on electronic databases to identify articles 
reporting double-blind randomized controlled trials investigating the efficacy of biologic agents 
indicated for monotherapy. Efficacy was assessed using American College of Rheumatology 
(ACR) 20, 50, and 70 criteria at 16–24 weeks. Relative efficacy was estimated using Bayesian 
mixed-treatment comparison models. Outcome measures were expressed as odds ratio and 
95% credible intervals.
Results: Ten randomized controlled trials were selected for data extraction and analysis. Mixed-
treatment comparison analysis revealed that tocilizumab offered 100% probability of being the 
best treatment for inducing an ACR20 response versus placebo, methotrexate, adalimumab, 
or etanercept. Likewise, for ACR50 and ACR70 outcome responses, tocilizumab had a 99.8% 
or 98.7% probability of being the best treatment, respectively, compared to other treatments or 
placebo. Tocilizumab increased the relative probability of being the best treatment (vs metho-
trexate) by 3.2-fold (odds ratio: 2.1–3.89) for all ACR outcomes.
Conclusion: Tocilizumab offered the greatest possibility of obtaining an ACR20, ACR50, and 
ACR70 outcome vs other monotherapies or placebo.
Keywords: biologics, meta-analysis, mixed-treatment comparison, monotherapy, rheumatoid 
arthritis, tocilizumab
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that 
according to recent estimates affects approximately 1% of the adult population in devel-
oped countries.1,2 Conventional disease-modifying antirheumatic drugs (DMARDs) 
such as methotrexate (MTX) are given as first-line treatment alone or in combination 
with another DMARD.3 For the past 20 years, biological DMARDs (bDMARDs) have 
become available that target specific parts of the immune system and offer an impor-
tant alternative for patients refractory to or intolerant to conventional DMARDs, or 
where continued therapy with a DMARD is inappropriate/contraindicated.3 Although 
most patients who are eligible for biological therapy maintain treatment with MTX 
or another synthetic DMARD, up to 40% discontinue or show poor adherence, due to 
side effects4 or preference.5 As a consequence, approximately a third of patients take 
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biologics as monotherapy (according to data from biologic 
registries and US claims databases).6–13 Among the differ-
ent biological therapies available, only the tumor necrosis 
factor-α (TNF-α) inhibitors certolizumab pegol, etanercept, 
and adalimumab are currently approved as monotherapy 
for patients with RA in Europe and USA.14–16 In addition, in 
Europe and USA, the interleukin-6 inhibitor tocilizumab is 
licensed for use as monotherapy.17 Other biologics such as 
infliximab and golimumab (both TNF-α inhibitors) and the 
CD-20 inhibitor rituximab are approved only with MTX.18–20 
Other non-TNF-α inhibitors tofacitinib/anakinra and abata-
cept are only approved as monotherapy in USA.21,22
While it is true that many pivotal RCTs have already 
demonstrated superior efficacy of these biological agents 
compared to placebo or conventional DMARDs, there are 
currently limited head-to-head RCTs for these biological 
agents. Regarding biologics indicated for monotherapy 
use, only one trial has specifically examined the superior-
ity of a biological drug directly compared to another.23 The 
ADACTA trial, a multicentric, randomized double-blind 
controlled trial included 325 patients and examined the effi-
cacy and safety of tocilizumab compared to adalimumab at 
24 weeks. Tocilizumab was shown to be superior as measured 
by disease activity score in 28 joints (DAS-28), while safety 
profiles remained similar between the two treatments.23 While 
this trial has shown superiority of tocilizumab compared 
with adalimumab in monotherapy in the setting of RA, no 
published RCT provides head-to-head efficacy evidence 
comparing all biological agents indicated for monotherapy 
in RA patients. In the absence of these trials, which would 
also be difficult to justify due to the cost and time involved, 
the mixed-treatment comparison (MTC) statistical method 
allows to estimate through direct and indirect comparisons, 
the efficacy of different drugs from several trials.24,25 Different 
MTC methods have been considered in the literature, and one 
is based on Bayesian principles. The Bayesian MTC approach 
is recognized for having greater flexibility and capacity for 
handling complex modeling structures compared to other 
non-Bayesian approaches.26,27
While several recent systematic reviews and meta-analyses 
(including Bayesian MTC analyses) have examined the 
efficacy of biologic therapies in the treatment of RA, some 
studies have either examined the anti-TNF-α class of bio-
logics only,28–30 or included studies using doses prescribed 
in the US,31 while the majority of these reviews did not 
compare the effect of biologics administered as monotherapy 
only.24,25,28–34 In almost all of these studies, the American 
College of Rheumatology (ACR) criteria outcome measure 
was chosen to express relative efficacy between treatments.35 
A recent previous systematic review and meta-analysis has 
compared the relative efficacy of EU-licensed biologic com-
bination therapy or monotherapy for patients intolerant of 
or contraindicated to continue MTX.36 However, this study 
reported results on the efficacy of biologic agents used in 
monotherapy against placebo and not against MTX. It is 
already known that biologic agents are more efficacious than 
placebo, however, and more importantly, we want to know 
if and to what extent they are more effective than MTX. In 
addition, this study did not include the recent ADACTA 
study, the only head-to-head RCT trial performed to date 
comparing biologics indicated for use as monotherapy.23
In the present analysis, we used a Bayesian MTC meth-
odology to determine the best choice of treatment among 
currently available biologic therapies at common doses 
(prescribed within the EU), administered as monotherapy and 
assessed by ACR response (ACR20, ACR50, and ACR70) 
at 16–24 weeks compared to MTX.
Methods
search and selection
The authors advise that since ethics approval was already 
obtained for each study included in this meta-analysis, no for-
mal ethics approval was required to undertake this analysis. 
A literature search was only performed on articles published 
in peer-reviewed journals, to improve the methodological 
quality of studies examined and conclusions drawn. A sys-
tematic electronic search was performed for the period using 
the following databases: PubMed/Medline, INIST (Institut 
de l’Information Scientifique et Tecnique), Science Direct, 
Google Scholar, and Cochrane Library between July and 
September 2013. Text words that were applied to the search 
field included “rheumatoid arthritis” AND (etanercept OR 
certolizumab OR adalimumab OR tocilizumab). The search 
was repeated, filtering for “randomized controlled trials”. 
We only included clinical trials published in English language 
and excluded reviews, letters, and abstracts.
Study eligibility criteria
Criteria for inclusion of studies in the present MTC analysis 
included double-blind RCTs, with primary outcomes of 
ACR20, ACR50, or ACR70 response to treatment at 16 weeks 
or greater. Subjects included adults aged 18 years or older 
who met the 1987 revised ACR criteria for RA. Interventions 
included any biologic agent licensed for use as monotherapy 
in the EU in case of intolerance to MTX or previous biological 
treatment. Comparator drugs included DMARDs (eg, MTX), 
bDMARDs, or placebo. ACR20, ACR50, or ACR70 response 
was defined as a 20%, 50%, or 70% improvement in tender 
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and swollen joints, and same level of improvement in at least 
three of the following five disease parameters: patient’s global 
assessment of disease activity, physician’s global assessment of 
disease activity, patient’s assessment of pain, patient’s assess-
ment of physical disability (measured by the Health Assess-
ment Questionnaire-Disability Index), and level of acute-phase 
reactants.35 RCTs having continuous clinical values as primary 
endpoints, such as DAS-28 or radiological outcome, were 
excluded as were studies comparing different dosing regimens 
(not used in clinical practice) of the same agent or studies 
examining treatments in combination (not monotherapy).
Statistical analysis
Bayesian MTC meta-analysis was conducted on the pri-
mary trial endpoints ACR20, ACR50, and ACR70 in all 
studies that met inclusion criteria after careful assessment 
of heterogeneity across trials, in terms of subject char-
acteristics, trial methodologies, and treatment protocols. 
WinBUGS 1.4 statistical software37,38 (MRC Biostatistics 
Unit, Cambridge, UK) was used to perform MTC based 
on Markov Chain Monte Carlo (MCMC) methods. The 
MTC method represents a generalization of meta-analysis, 
whereby possible comparisons not addressed within the 
individual primary trials can be performed.39 This method 
preserves within-trial randomization and enables all avail-
able direct and indirect comparisons between treatments 
to be made in one analysis.40 Results of all trials were ana-
lyzed simultaneously by a fixed-effect model.41,42 Primary 
outcomes were expressed as odds ratios (OR) and corre-
sponding 95% credible intervals (CrI) (Bayesian equivalent 
of confidence interval) comparing the different treatments. 
For all analyses, we chose proper noninformative prior dis-
tributions for parameters included in the model. Analysis 
was implemented using Gibbs sampler algorithm through 
WinBUGS statistical software, based on 30,000 iterations 
after a burn-in of 2000. The value taken as the MCMC 
estimate was the mean over iteration sampled, starting with 
the first iteration following burn-in. Satisfactory conver-
gence was verified by trace plots, monitoring Monte Carlo 
errors, and with Gelman–Rubin diagnostics. Differences 
in baseline demographic and clinical characteristics for 
treatment groups were analyzed by one-way ANOVA using 
Instat software (GraphPad, La Jolla, CA, USA); a P-value 
of #0.05 was considered statistically significant.
Results
Trial flow and study characteristics
Figure 1 shows a flow diagram of the selection process. Our 
initial search returned 994 distinct results, of which only 
47 were potentially relevant based on reading their title 
and abstract. A further 37 studies were excluded because 
they did not meet inclusion criteria or did not examine RA 
patients or had follow-up periods ,16 weeks. Data regard-
ing certolizumab pegol were not included in the analysis as 
the study reported data on a 12-week, double-blind phase, 
followed by another 12 weeks performed in open label, 
while all other included studies reported data on the basis 
of a 24-week (apart from one study, which had a follow-up 
period of 16 weeks) double-blind follow-up. In RCTs, 
where the efficacy of tocilizumab not associated to MTX vs 
tocilizumab associated to MTX was tested, they were not 
included in the analysis as the comparator was represented 
by an association of a biologic agent with a DMARD, and in 
the present analysis, only monotherapies of biologic agents 
were included. Ten RCTs met the selection criteria and were 
included in the final meta-analysis.23,43–51 Characteristics of 
the ten studies are presented in Table 1. All ten studies were 
randomized double-blind and conducted between 1999 and 
2013. Study duration ranged from 24 weeks to 2 years, and 
sample size (intention-to-treat population) ranged from 102 
to 531 patients. All studies had a follow-up period of at 
least 16 weeks, with two studies having a follow-up of 146 
and 2 years,47 respectively. Five studies examined the effect 
of tocilizumab (8 mg/kg, intravenous, every 4 weeks) to 
comparator (MTX, placebo, or adalimumab), while three 
studies examined the effect of etanercept (25 mg, subcutane-
ous, twice-weekly) to a comparator (placebo or MTX), and 
two studies compared the efficacy of adalimumab (40 mg, 
subcutaneous, every second week) to either MTX or placebo. 
Treatment doses of etanercept, adalimumab, and tocilizumab 
were standard recommended doses, and MTX doses ranged 
from 6.9 to 20 mg/wk.
Patient characteristics
Baseline clinical characteristics for patients (N=3,210) in the 
ten trials are presented in Table 2. The proportion of female 
patients ranged from 74% to 83%, and mean age ranged from 
50 to 54 years. Disease duration and markers of disease activ-
ity (erythrocyte sedimentation rate and C-reactive protein) 
showed normal variation between the ten studies. Pooled 
analysis of baseline characteristics by treatment arm showed 
no difference in the proportion of female patients or mean 
age, whereas a statistically significant difference in disease 
duration and disease activity markers emerged. However, 
these differences were mainly attributed to higher values 
for placebo-treated patients, based on two studies only.43,45 
DAS-28, erythrocyte sedimentation rate, and C-reactive 
protein values for biologic treatments were not significantly 
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Figure 1 Selection process for studies included in meta-analysis.
Abbreviations: INIST, Institut de l’Information Scientifique et Technique; MTX, methotrexate; RA, rheumatoid arthritis; RCT, randomized controlled trial.
Table 1 Characteristics of trials included in meta-analysis
Study (year) ITT Geographic origin Drug tested Comparator Study duration
Moreland et al43 (1999) 158 naM Etanercept (25 mg, sc, tw) Placebo 26 weeks
Bathon et al44 (2000) 424 naM Etanercept (25 mg, sc, tw) MTX (19 mg/week) 24 weeks
Klareskog et al46 (2004) 451 EUR, AUS, ISR Etanercept (25 mg, sc, tw) MTX (17.2 mg/week) 1 year
van de Putte et al45 (2004) 223 EUR, CAN, AUS Adalimumab (40 mg, sc, eow) Placebo 26 weeks
Breedveld et al47 (2006) 531 EUR, NAM, AUS Adalimumab (40 mg, sc, eow) MTX (20 mg/week) 2 years
Maini et al48 (2006) 102 EUR Tocilizumab (8 mg, iv, efw) MTX (10–17.5 mg/week) 16 weeks
nishimoto et al49 (2007) 302 JaP Tocilizumab (8 mg, iv, efw) DMaRDs + MTX (6.9 mg/week) 24 weeks
Jones et al50 (2010) 524 NAM, ISR Tocilizumab (8 mg, iv, efw) MTX (15.5 mg/week) 24 weeks
nishimoto et al51 (2009) 125 JaP Tocilizumab (8 mg, iv, efw) MTX (8 mg/week) 24 weeks
Gabay et al23 (2013) 325 NAM, SAM, AUSAS, EUR Tocilizumab (8 mg, iv, efw) Adalimumab (40 mg, sc, eow) 24 weeks
Abbreviations: AUS, Australia; AUSAS, Australasia; CAN, Canada; DMARD, disease-modifying antirheumatic drug; efw, every four weeks; eow, every other week; EUR, 
Europe; ISR, Israel; ITT, intention to treat population; iv, intravenous; JAP, Japan; MTX, methotrexate; NAM, North America; SAM, South America; sc, subcutaneous; tw, 
twice weekly.
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Table 2 Baseline demographic and clinical characteristics
Study (year) Female  
(%)
Mean age  
(years)
Disease duration  
(years)
MTX  
naïve
MTX-IR Mean previous  
DMARD
DAS-28 ESR  
(mm/h)
CRP  
(mg/dL)
Moreland et al43 (1999) 74 53 11 no Yes 3.3 N/A 35 4.7
Bathon et al44 (2000) 74 51±13 1±0.9 Yes no 0.5±0.7 N/A N/A 3.3±4
Klareskog et al46 (2004) 77 52.5±12.4 6.8±5.4 no Yes 2.3±1.4 5.5±1.2 N/A 2.9±3.3
van de Putte et al45 (2004) 79.6 52.7±13.3 10.6±6.9 no Yes 3.8±21.8 7.07±0.86 55.8±27 5.26±3.7
Breedveld et al47 (2006) 77.4 52.1±13.5 0.7±0.8 Yes no 2.7± (1–7) 6.4±0.9 N/A 4.1±3.9
Maini et al48 (2006) 73.1 50.1 0.8 no Yes 1.2±1.3 6.43 39 2.2
nishimoto et al49 (2007) 80.8 52.9±11.6 2.2±1.4 no Yes 2.7± (1–7) 6.5±0.8 71±25.2 4.9±2.9
Jones et al50 (2010) 83 50.7±13.1 6.4±7.9 Part Part 1.2±1.3 6.8±1 49.9±27.9 3.0±3.3
nishimoto et al51 (2009) 82.4 52.6±10.6 8.5±8.4 no Yes 3.3 (1–8) 6.1±0.9 51.9±27.7 3.0±2.0
Gabay et al23 (2013) 79 54.4±13 7.3±8.1 no Yes 2±1.1 6.7±0.9 50.5±20.9 2.6±3.1
Note: Data presented as mean ± standard deviation or (range).
Abbreviations: CRP, C-reactive protein; DAS-28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; 
MTX, methotrexate; MTX-IR, methotrexate inadequate response patients; N/A, data not available; Part, partial.
different from each other (Table 2). The magnitude of 
ACR response in treatment arms was similar between the 
ten studies, ranging from 50% to 80% for ACR20, 15% to 
30% for ACR50, and 15% to 30% for ACR70 (Table 3). 
ACR response was also similar in studies including early 
RA patients (four studies, mean: 1 year disease duration) vs 
studies including patients with established RA (six studies, 
mean: 8.4 years disease duration) (data not shown).
MTC analysis of ACR response
MTC analysis revealed that for ACR20, tocilizumab had a 
probability of 100% of being the best treatment in terms of 
producing an ACR20 response at 24 weeks compared with 
placebo, MTX, adalimumab, or etanercept (Table 4). This 
equated to a relative odds of being the best treatment of 
approximately 3-fold greater for tocilizumab compared to 
either MTX (OR =3.19, 95% CrI =2.46–4.09), etanercept 
(OR =3.89, 95% CrI =2.46–5.81), or adalimumab (OR =2.49, 
95% CrI =1.61–3.71) (Table 4). As expected, placebo did 
Table 3 ACR20/50/70 response in trials included in meta-analysis
Study (year) Disease  
duration (years)
ACR20 P-value ACR50 P-value ACR70 P-value
Moreland et al43 (1999) 11 E: 59%, P: 10% 0.0001 E: 40%, P: 5% 0.001 E: 15%, P: 1% 0.031
Bathon et al44 (2000) 1±0.9 e: ∼60%, M: ∼60% ns e: ∼40%, M: ∼30% ns e: ∼20%, M: ∼15% ,0.05
Klareskog et al46 (2004) 6.8±5.4 E: 70%, M: 70% ns E: 40%, M: 40% ns E: 15%, M: 15% ns
van de Putte et al45 (2004) 10.6±6.9 A: 53.4%, P: 19.1% #0.001 A: 35%, P: 8.2% #0.001 A: 18.4%, P: 1.8% #0.001
Breedveld et al47 (2006) 0.7±0.8 A: 54%, M: 63% ,0.05 A: 41%, M: 46% ns A: 26%, M: 28% ns
Maini et al48 (2006) 0.8 T: 63%, M: 41% ,0.05 T: 41%, M: 29% ns T: 16%, M: 16% ns
nishimoto et al49 (2007) 2.2±1.4 T: 78%, M: 34% ,0.001 T: 64%, M: 13% ,0.001 T: 44%, M: 6% ,0.001
Jones et al50 (2010) 6.4±7.9 T: 69.9%, M: 52.5% ,0.001 T: 44.1%, M: 33.5% ,0.002 T: 28%, M: 15.1% ,0.001
nishimoto et al51 (2009) 8.5±8.4 T: 80.3%, M: 25% ,0.001 T: ∼55%, M: ∼18% N/A T: ∼32%, M: ∼15% N/A
Gabay et al23 (2012) 7.3±8.1 T: 65%, A: 49.4% 0.0038 T: 47.2%, A: 27.8% 0.0002 T: 32.5%, A: 17.9% 0.0023
Note: P-values represent statistically significant differences between the two treatment arms reported in each study.
Abbreviations: A, adalimumab; ACR, American College of Rheumatology; E, etanercept; M, methotrexate; N/A, not available; NS, not statistically significant; P, placebo; 
T, tocilizumab.
not offer significant probability of attaining ACR20 response 
over other treatments (Figure 2A), and etanercept only offered 
marginal advantage compared to MTX. A similar benefit was 
also observed for ACR50 response, whereby tocilizumab 
had a 99.8% probability of being the best treatment com-
pared to etanercept, which had a probability of 0.14%, and 
adalimumab, a probability of 0.02% (Table 5). The relative 
odds of being the best treatment was approximately 2.5-fold 
greater for tocilizumab compared to MTX (OR =3.1, 95% CrI 
=2.33–3.97), etanercept (OR =2.11, 95% CrI =1.27–3.31), 
or adalimumab (OR =2.25, 95% CrI =1.39–3.47) (Table 5). 
Interestingly, little difference was noted between adalimumab 
and etanercept, while both etanercept and adalimumab 
fared better than MTX (Figure 2B). With regard to ACR70, 
tocilizumab showed a probability of 98.7% of being the best 
treatment in inducing ACR70 remission compared to etan-
ercept, which had a probability of 1.2%, and adalimumab, 
which had a probability of 0.12% (Table 6). The relative 
odds of being the best treatment in inducing ACR70 response 
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was approximately 2.5-fold greater for tocilizumab com-
pared to MTX (OR =3.56, 95% CrI =2.51–4.92), etanercept 
(OR =2.14, 95% CrI =1.11–3.74), or adalimumab (OR =2.27, 
95% CrI =1.32–3.73) (Table 6). Similar to ACR50 outcome, 
both etanercept and adalimumab offered greater probability 
of attaining ACR70 response compared to MTX (Figure 2C). 
For all ACR outcomes, tocilizumab increased the relative 
probability of being the best treatment by approximately 
3-fold (OR =2.1–3.89) compared to other treatments, (data 
not shown).
Table 4 Results of mixed-treatment comparison for each drug in being the most effective treatment for obtaining ACR20 
improvement
Comparison Odds  
ratioa
Lower 95%  
CrI
Higher 95%  
CrI
Probability of best  
treatment for ACR20 (%)
Rank
Tocilizumab vs placebo 0.066 0.035 0.11 100 1
Etanercept vs placebo 0.25 0.13 0.42 0 nR
Adalimumab vs placebo 0.16 0.09 0.26 0 nR
Methotrexate vs placebo 0.21 0.11 0.35 0 nR
Methotrexate vs etanercept 0.85 0.58 1.19 na na
Methotrexate vs adalimumab 1.34 0.82 2.07 na na
Methotrexate vs tocilizumab 3.19 2.46 4.09 na na
Etanercept vs adalimumab 1.62 0.91 2.68 na na
Etanercept vs tocilizumab 3.89 2.46 5.81 na na
Adalimumab vs tocilizumab 2.49 1.61 3.71 na na
Note: aOdds ratio represents the ratio of being the most effective treatment for one drug compared to another (eg, adalimumab vs tocilizumab, represents a 2.49-fold 
difference, favoring tocilizumab).
Abbreviations: ACR, American College of Rheumatology; CrI, credible interval; NA, not applicable; NR, not relevant.
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Figure 2 Relative odds of different drug comparisons being the most effective treatment for obtaining improvement in ACR outcome.
Notes: (A) ACR20, (B) ACR50, and (C) ACR70 outcomes. Data presented as odds ratio for different drug comparisons. Solid line denotes mean odds ratio for all treatment 
comparisons. Black dotted-line denotes an odds ratio of 1. For clarity, each figure is divided into three sections by treatment type vs methotrexate; biologic vs biologic; and 
vs placebo.
Abbreviations: A, adalimumab; ACR, American College of Rheumatology; E, etanercept; M, methotrexate; P, placebo; T, tocilizumab.
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Discussion
This meta-analysis included ten double-blind randomized 
controlled trials including 3,210 patients comparing a bio-
logic to placebo or MTX and another biologic (in one trial 
only), having the same endpoint since only one head-to-head 
trial’s evidence is currently available.23 Since our main aim 
in the present study was to examine practical parameters that 
can impact upon real-life decisions within the rheumatology 
clinic, we specifically focused on the relative efficacy of cur-
rently licensed doses of commonly used biologic treatments 
administered as monotherapy for RA within the European 
Union.
All studies included in the MTC analysis were similar 
with regard to average age of patients, disease duration, and 
baseline disease severity, excluding these factors as sources 
of heterogeneity across trials and, therefore, bias in the indi-
rect estimates. The main findings from this MTC analysis 
demonstrate that tocilizumab grants the largest possibility 
(approximately 3-fold greater) of obtaining ACR20, ACR50, 
and ACR70 outcome compared to all other drugs, when 
administered as monotherapy.
The design of this analysis granted the possibility of 
confirming that all biologic drugs are better than placebo; 
however, for etanercept and adalimumab, a statistically 
significant difference with MTX was not observed, while 
tocilizumab was found to be statistically superior to MTX 
for all three ACR endpoints. Etanercept and adalimumab 
were found to be comparable to MTX, in terms of granting 
an ACR20 response, but were then slightly better than MTX 
for ACR50 and ACR70 and always found to be better than 
placebo. Tocilizumab was always superior to placebo, MTX, 
etanercept, and adalimumab for all endpoints.
Several recent systematic reviews and meta-analysis 
(including Bayesian MTC analyses) have already compared the 
efficacy of biologic therapies for the treatment of RA.24,25,28–34 
However, while some studies have either examined the 
Table 5 Results of mixed-treatment comparison for each drug in being the most effective treatment for obtaining ACR50 
improvement
Comparison Odds  
ratioa
Lower  
95% CrI
Higher  
95% CrI
Probability of best  
treatment for ACR50 (%)
Rank
Tocilizumab vs placebo 0.05 0.012 0.13 99.83 1
Etanercept vs placebo 0.11 0.026 0.25 0.14 2
Adalimumab vs placebo 0.12 0.026 0.29 0.023 3
Methotrexate vs placebo 0.16 0.04 0.39 0.003 4
Methotrexate vs etanercept 1.51 1 2.2 na na
Methotrexate vs adalimumab 1.44 0.82 2.33 na na
Methotrexate vs tocilizumab 3.06 2.33 3.97 na na
Etanercept vs adalimumab 0.99 0.49 1.79 na na
Etanercept vs tocilizumab 2.11 1.27 3.31 na na
Adalimumab vs tocilizumab 2.25 1.39 3.47 na na
Note: aOdds ratio represents the ratio of being the most effective treatment for one drug compared to another (eg, adalimumab vs tocilizumab, represents a 2.25-fold 
difference, favoring tocilizumab).
Abbreviations: ACR, American College of Rheumatology; CrI, credible interval; NA, not applicable.
Table 6 Results of mixed-treatment comparison for each drug in being the most effective treatment for obtaining ACR70 
improvement
Comparison Odds  
ratioa
Lower  
95% CrI
Higher  
95% CrI
Probability of best  
treatment for ACR70 (%)
Rank
Tocilizumab vs placebo 0.05 0.00008 0.24 98.68 1
Etanercept vs placebo 0.11 0.002 0.45 1.19 2
Adalimumab vs placebo 0.12 0.002 0.54 0.12 3
Methotrexate vs placebo 0.19 0.003 0.81 0.003 4
Methotrexate vs etanercept 1.78 1 2.88 na na
Methotrexate vs adalimumab 1.68 0.86 2.95 na na
Methotrexate vs tocilizumab 3.56 2.51 4.92 na na
Etanercept vs adalimumab 1.01 0.42 2.06 na na
Etanercept vs tocilizumab 2.14 1.11 3.74 na na
Adalimumab vs tocilizumab 2.27 1.32 3.73 na na
Note: aOdds ratio represents the ratio of being the most effective treatment for one drug compared to another (eg, adalimumab vs tocilizumab, represents a 2.27-fold 
difference, favoring tocilizumab).
Abbreviations: ACR, American College of Rheumatology; CrI, credible interval; NA, not applicable.
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anti-TNF-α class of biologics only,28–30 virtually all of these 
studies based their analysis on the efficacy of biologics used in 
combination with conventional DMARDs such as MTX.24,25,28–34 
Since it has been established that up to one-third of RA patients 
take biologics as monotherapy, as they are either refractory 
or intolerant to MTX or where a conventional DMARD is 
contraindicated,5–13 it is essential to have an awareness of the 
best treatment options for these patients.
In the few MTC analyses that specifically examined 
the efficacy of tocilizumab, this IL-6 inhibitor was as 
good if not better than other biologics examined for ACR 
response.25,32–34,36 Likewise, findings from our MTC analysis 
indicate a probability of 98.7% for tocilizumab being the 
best treatment for ACR70 compared to ,1% for other 
treatments. We have also calculated credible sets for best 
treatment ranks and noted that they did not overlap and 
were not wide ranging (data not shown). It is worth noting 
that the ACR70 response in studies included in the present 
analysis was approximately 30%, double that of comparator 
treatments, and higher than other biologic treatments. In the 
only Bayesian network meta-analysis that has compared the 
efficacy of biologic agents as monotherapy, tocilizumab was 
found to have a probability of being the best treatment of 
69.2% for all three ACR endpoints vs placebo,36 while our 
study also investigated a comparison against MTX. In real 
life, we only have the possibility to treat patients with a 
biologic or MTX, not with placebo. This is the added value 
of our study, since we already know that active treatment is 
better than placebo (as monotherapy). In this comprehensive 
analysis by Orme et al36 the follow-up period for selection 
was 12–30 weeks, and the only head-to-head trial examining 
tocilizumab compared to another biologic23 was not included 
in their analysis. Furthermore, in that study, comparison was 
only made to placebo. A recent update on the 2013 European 
League Against Rheumatism (EULAR) recommendations3 
for the management of RA regarding efficacy, bDMARDs 
confirmed the efficacy of bDMARDs and conventional 
synthetic DMARDs vs conventional DMARDs alone (level 
1B evidence).52 It also emerged from this systematic review 
(conducted from 2009 to 2013) that biological DMARDs and 
MTX combination therapy was more efficacious compared 
to all biological DMARD classes (1B). Regardless, although 
the majority of patients are eligible for biological therapy 
with MTX or another synthetic DMARD, that has proven 
efficacy, as many as 40% discontinue due to poor adherence, 
side effects,4 or preference.5 Consequently, about a third of 
patients will be treated with biologics as monotherapy.6–13
If results from the present MTC are taken into consid-
eration for decision making, patients should be treated with 
MTX if patients were not previously declared intolerant to 
MTX or MTX nonresponders; while for those patients who 
are intolerant to MTX or not adherent, they should be switched 
to tocilizumab-based therapy in an attempt to achieve ACR20, 
ACR50, and ACR70 for a greater number of patients. For new 
patients who cannot undergo MTX-based therapy, tocilizumab 
should represent the first choice in monotherapy treatment. 
Considering these three biologics (etanercept, adalimumab, 
and tocilizumab), in absence of data from this MTC analysis, if 
a new patient was required to initiate a biologic monotherapy, 
clinicians would have a 66% chance of making the wrong 
decision in giving any of these treatments in an attempt to 
administer the best treatment for achieving clinical improve-
ment, as established by ACR criteria. In contrast, following 
this MTC, clinicians now have a 98% of probability of admin-
istering the best treatment for achieving ACR improvement 
criteria when administering tocilizumab (corresponding to a 
2% chance of making the wrong decision).
Aside from assessing the relative therapeutic efficacy of 
one biologic compared to another, the issue of which choice 
of therapy is cost-effective is also an important consideration. 
Two recent meta-analyses were specifically designed to 
evaluate the cost-utility and value of reducing the uncertainty 
associated with the decision to use first-line biologic treat-
ment after failure or inadequate response to DMARDs in 
moderate-to-severe RA.53,54 Both of these studies concluded 
that replacing another biologic therapy with tocilizumab 
or adding tocilizumab to current standard care was a cost-
effective strategy in the treatment of RA patients, equating 
to €17,100 and €20,000 quality-adjusted life years for the 
two studies, respectively.53,54 Furthermore, a recent network 
analysis by Jansen et al55 compared biologics as mono-
therapy or in combination with MTX in terms of patient 
reported outcomes in RA patients who had an inadequate 
response to conventional DMARDs. This analysis revealed 
that tocilizumab was associated with a greater improvement 
in pain and self-reported disease activity compared to anti-
TNF inhibitors. In patients intolerant to MTX, tocilizumab 
appears to offer a greater possibility of improved patient 
reported outcomes compared to anti-TNF monotherapy and 
may therefore represent an attractive therapeutic option in 
this patient population. In addition to efficacy, tolerability 
and safety of different biologics are important considerations 
for the choice of therapy in RA patients. This component was 
not assessed in the present analysis, but has been extensively 
examined in numerous clinical trials23,43–51 and subsequently 
in recent reviews56 and meta-analyses.57–60 One meta-analysis 
by Burmester et al57 compared the safety profile of tocili-
zumab to other biological agents and showed similar rates 
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of serious adverse events, serious infections, lymphoma, and 
congestive heart failure. In addition, an indirect comparison 
of abatacept, golimumab, and rituximab with tocilizumab 
in patients with RA, following inadequate response to TNF 
inhibitors, showed similar safety profiles.58 Findings from 
these meta-analyses and other studies have since been con-
solidated in recent EULAR consensus statements.59,60
The present MTC does have some potential limitations. 
The present MTC analysis used ACR response (between 16 
and 24 weeks) as the outcome criteria. Although the inclu-
sion of other endpoint measures (such as erosion or structural 
damage assessed by radiographic scores) were considered 
a priori, this was not possible due to inconsistency of these 
measures in RCTs examined. Further indirect analysis specifi-
cally examining whether the relative advantage by tocilizumab 
in terms of ACR outcome measures can also be extended to 
these other hard-endpoints at not only 24 weeks, but where 
possible, longer follow-up periods (eg, 1 year) would be worth 
investigating. Less heterogeneity among the included studies 
with regard to disease duration and follow-up period would 
have been desired. However, careful assessment of trial meth-
odologies, treatment protocols, and patient characteristics did 
not reveal any association with extent of outcome that was 
not attributed to treatment alone. The ACR20 response is 
chosen as a primary endpoint in most RA clinical trials, and 
ACR50 and ACR70 responses are usually also reported. As 
previously described, these measures are a binomial reduction 
built on the underlying continuous distribution of response.32 
Although this outcome measure has been frequently used 
in other MTC analyses,24,25,28–34,36 it has more recently come 
under criticism for being limited by its lack of sensitivity to 
change in binary outcome measures.29 Additional continuous 
outcome criteria (eg, the Health Assessment Questionnaire 
multiplier) may increase sensitivity and complement binary 
measures.61 It is also important to mention that the ADACTA 
trial23 was performed more recently compared to other older 
trials included in our analysis43–51 and this time difference may 
result in unforeseen differences in patient clinical character-
istics. The present analysis compared the relative efficacy 
of different biologic agents administered as monotherapy 
for the treatment of RA. This analysis did not compare the 
safety profile of these biological agents, which is an essential 
component when choosing the best therapeutic option for a 
patient. One perceived weakness of this analysis is the range 
in difference in MTX doses among the different studies 
included. However, the MTX groups of all analyzed biologic 
agents were pooled together in the Bayesian meta-analysis, 
thus granting an acceptable approximation of data. There-
fore, this analysis was not based on the direct confrontation 
of a single biologic agent with its control group, but on the 
indirect confrontation of all biologic agents with the pooled 
group of all control arms. For this reason, the difference in 
the MTX dosage (particularly for the two Japanese studies49,51 
included that had low, fixed MTX doses) for various control 
groups exerts only a small effect on the analysis performed. 
To verify this, analysis was repeated without the inclusion of 
the two Japanese studies, and although the OR was marginally 
reduced, tocilizumab still emerged as the best treatment in 
obtaining ACR20, ACR50, and ACR70 outcome compared 
to all other drugs (data not shown).
This analysis includes indirect comparisons across differ-
ent clinical trials and is not a replacement for head-to-head 
data. Findings from the present analysis should be interpreted 
with caution, taking into consideration the aforementioned 
limitations associated with MTC. However, in the absence 
of these trials, Bayesian MTC models are recognized as 
accepted methodologies for the comparison of therapies and 
essential for therapeutic decision-making.
Conclusion
Findings derived from the present analysis indicate that 
treatment with tocilizumab allows a significantly greater 
proportion of patients to attain clinical benefit within 
6 months compared to other biologic therapies. Although 
most patients who are eligible for biological therapy will still 
continue treatment with MTX or another synthetic DMARD, 
a significant proportion of patients at some stage will require 
monotherapy. Tocilizumab may well be considered as a first-
choice, cost-effective treatment in these patients. Further 
comparative efficacy trials to directly compare targeted treat-
ments for RA are clearly required. For the moment, MTC 
analysis, as presented here, will play an important role in 
aiding day-to-day decision-making in clinical practice.
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